Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.
Identifieur interne : 001628 ( PubMed/Corpus ); précédent : 001627; suivant : 001629Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.
Auteurs : Jun Liu ; Peng Wu ; Feng Gao ; Jianxun Qi ; Ai Kawana-Tachikawa ; Jing Xie ; Christopher J. Vavricka ; Aikichi Iwamoto ; Taisheng Li ; George F. GaoSource :
- Journal of virology [ 1098-5514 ] ; 2010.
English descriptors
- KwdEn :
- Adult, Amino Acid Sequence, Binding Sites, Cell Line, Cells, Cultured, Epitope Mapping (methods), Epitopes, T-Lymphocyte (chemistry), Epitopes, T-Lymphocyte (genetics), Epitopes, T-Lymphocyte (immunology), Female, HLA-A Antigens (chemistry), HLA-A Antigens (genetics), HLA-A Antigens (immunology), Humans, Hydrogen Bonding, Leukocytes, Mononuclear (chemistry), Leukocytes, Mononuclear (immunology), Leukocytes, Mononuclear (virology), Male, Models, Molecular, Molecular Sequence Data, Nucleocapsid Proteins (chemistry), Nucleocapsid Proteins (genetics), Nucleocapsid Proteins (immunology), Peptide Fragments (chemistry), Peptide Fragments (genetics), Peptide Fragments (immunology), Protein Folding, SARS Virus (chemistry), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), T-Lymphocytes, Cytotoxic (chemistry), T-Lymphocytes, Cytotoxic (immunology).
- MESH :
- chemical , chemistry : Epitopes, T-Lymphocyte, HLA-A Antigens, Nucleocapsid Proteins, Peptide Fragments.
- chemical , genetics : Epitopes, T-Lymphocyte, HLA-A Antigens, Nucleocapsid Proteins, Peptide Fragments.
- chemical , immunology : Epitopes, T-Lymphocyte, HLA-A Antigens, Nucleocapsid Proteins, Peptide Fragments.
- chemistry : Leukocytes, Mononuclear, SARS Virus, T-Lymphocytes, Cytotoxic.
- genetics : SARS Virus.
- immunology : Leukocytes, Mononuclear, SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes, Cytotoxic.
- methods : Epitope Mapping.
- virology : Leukocytes, Mononuclear, Severe Acute Respiratory Syndrome.
- Adult, Amino Acid Sequence, Binding Sites, Cell Line, Cells, Cultured, Female, Humans, Hydrogen Bonding, Male, Models, Molecular, Molecular Sequence Data, Protein Folding.
Abstract
Antigenic peptides recognized by virus-specific cytotoxic T lymphocytes (CTLs) are presented by major histocompatibility complex (MHC; or human leukocyte antigen [HLA] in humans) molecules, and the peptide selection and presentation strategy of the host has been studied to guide our understanding of cellular immunity and vaccine development. Here, a severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein-derived CTL epitope, N1 (QFKDNVILL), restricted by HLA-A*2402 was identified by a series of in vitro studies, including a computer-assisted algorithm for prediction, stabilization of the peptide by co-refolding with HLA-A*2402 heavy chain and β(2)-microglobulin (β(2)m), and T2-A24 cell binding. Consequently, the antigenicity of the peptide was confirmed by enzyme-linked immunospot (ELISPOT), proliferation assays, and HLA-peptide complex tetramer staining using peripheral blood mononuclear cells (PBMCs) from donors who had recovered from SARS donors. Furthermore, the crystal structure of HLA-A*2402 complexed with peptide N1 was determined, and the featured peptide was characterized with two unexpected intrachain hydrogen bonds which augment the central residues to bulge out of the binding groove. This may contribute to the T-cell receptor (TCR) interaction, showing a host immunodominant peptide presentation strategy. Meanwhile, a rapid and efficient strategy is presented for the determination of naturally presented CTL epitopes in the context of given HLA alleles of interest from long immunogenic overlapping peptides.
DOI: 10.1128/JVI.01464-10
PubMed: 20844028
Links to Exploration step
pubmed:20844028Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.</title><author><name sortKey="Liu, Jun" sort="Liu, Jun" uniqKey="Liu J" first="Jun" last="Liu">Jun Liu</name><affiliation><nlm:affiliation>Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Peng" sort="Wu, Peng" uniqKey="Wu P" first="Peng" last="Wu">Peng Wu</name></author><author><name sortKey="Gao, Feng" sort="Gao, Feng" uniqKey="Gao F" first="Feng" last="Gao">Feng Gao</name></author><author><name sortKey="Qi, Jianxun" sort="Qi, Jianxun" uniqKey="Qi J" first="Jianxun" last="Qi">Jianxun Qi</name></author><author><name sortKey="Kawana Tachikawa, Ai" sort="Kawana Tachikawa, Ai" uniqKey="Kawana Tachikawa A" first="Ai" last="Kawana-Tachikawa">Ai Kawana-Tachikawa</name></author><author><name sortKey="Xie, Jing" sort="Xie, Jing" uniqKey="Xie J" first="Jing" last="Xie">Jing Xie</name></author><author><name sortKey="Vavricka, Christopher J" sort="Vavricka, Christopher J" uniqKey="Vavricka C" first="Christopher J" last="Vavricka">Christopher J. Vavricka</name></author><author><name sortKey="Iwamoto, Aikichi" sort="Iwamoto, Aikichi" uniqKey="Iwamoto A" first="Aikichi" last="Iwamoto">Aikichi Iwamoto</name></author><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20844028</idno><idno type="pmid">20844028</idno><idno type="doi">10.1128/JVI.01464-10</idno><idno type="wicri:Area/PubMed/Corpus">001628</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001628</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.</title><author><name sortKey="Liu, Jun" sort="Liu, Jun" uniqKey="Liu J" first="Jun" last="Liu">Jun Liu</name><affiliation><nlm:affiliation>Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Peng" sort="Wu, Peng" uniqKey="Wu P" first="Peng" last="Wu">Peng Wu</name></author><author><name sortKey="Gao, Feng" sort="Gao, Feng" uniqKey="Gao F" first="Feng" last="Gao">Feng Gao</name></author><author><name sortKey="Qi, Jianxun" sort="Qi, Jianxun" uniqKey="Qi J" first="Jianxun" last="Qi">Jianxun Qi</name></author><author><name sortKey="Kawana Tachikawa, Ai" sort="Kawana Tachikawa, Ai" uniqKey="Kawana Tachikawa A" first="Ai" last="Kawana-Tachikawa">Ai Kawana-Tachikawa</name></author><author><name sortKey="Xie, Jing" sort="Xie, Jing" uniqKey="Xie J" first="Jing" last="Xie">Jing Xie</name></author><author><name sortKey="Vavricka, Christopher J" sort="Vavricka, Christopher J" uniqKey="Vavricka C" first="Christopher J" last="Vavricka">Christopher J. Vavricka</name></author><author><name sortKey="Iwamoto, Aikichi" sort="Iwamoto, Aikichi" uniqKey="Iwamoto A" first="Aikichi" last="Iwamoto">Aikichi Iwamoto</name></author><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Amino Acid Sequence</term><term>Binding Sites</term><term>Cell Line</term><term>Cells, Cultured</term><term>Epitope Mapping (methods)</term><term>Epitopes, T-Lymphocyte (chemistry)</term><term>Epitopes, T-Lymphocyte (genetics)</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>Female</term><term>HLA-A Antigens (chemistry)</term><term>HLA-A Antigens (genetics)</term><term>HLA-A Antigens (immunology)</term><term>Humans</term><term>Hydrogen Bonding</term><term>Leukocytes, Mononuclear (chemistry)</term><term>Leukocytes, Mononuclear (immunology)</term><term>Leukocytes, Mononuclear (virology)</term><term>Male</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Nucleocapsid Proteins (chemistry)</term><term>Nucleocapsid Proteins (genetics)</term><term>Nucleocapsid Proteins (immunology)</term><term>Peptide Fragments (chemistry)</term><term>Peptide Fragments (genetics)</term><term>Peptide Fragments (immunology)</term><term>Protein Folding</term><term>SARS Virus (chemistry)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>T-Lymphocytes, Cytotoxic (chemistry)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>HLA-A Antigens</term><term>Nucleocapsid Proteins</term><term>Peptide Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>HLA-A Antigens</term><term>Nucleocapsid Proteins</term><term>Peptide Fragments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term><term>HLA-A Antigens</term><term>Nucleocapsid Proteins</term><term>Peptide Fragments</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Leukocytes, Mononuclear</term><term>SARS Virus</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Leukocytes, Mononuclear</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Epitope Mapping</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Leukocytes, Mononuclear</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Amino Acid Sequence</term><term>Binding Sites</term><term>Cell Line</term><term>Cells, Cultured</term><term>Female</term><term>Humans</term><term>Hydrogen Bonding</term><term>Male</term><term>Models, Molecular</term><term>Molecular Sequence Data</term><term>Protein Folding</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antigenic peptides recognized by virus-specific cytotoxic T lymphocytes (CTLs) are presented by major histocompatibility complex (MHC; or human leukocyte antigen [HLA] in humans) molecules, and the peptide selection and presentation strategy of the host has been studied to guide our understanding of cellular immunity and vaccine development. Here, a severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein-derived CTL epitope, N1 (QFKDNVILL), restricted by HLA-A*2402 was identified by a series of in vitro studies, including a computer-assisted algorithm for prediction, stabilization of the peptide by co-refolding with HLA-A*2402 heavy chain and β(2)-microglobulin (β(2)m), and T2-A24 cell binding. Consequently, the antigenicity of the peptide was confirmed by enzyme-linked immunospot (ELISPOT), proliferation assays, and HLA-peptide complex tetramer staining using peripheral blood mononuclear cells (PBMCs) from donors who had recovered from SARS donors. Furthermore, the crystal structure of HLA-A*2402 complexed with peptide N1 was determined, and the featured peptide was characterized with two unexpected intrachain hydrogen bonds which augment the central residues to bulge out of the binding groove. This may contribute to the T-cell receptor (TCR) interaction, showing a host immunodominant peptide presentation strategy. Meanwhile, a rapid and efficient strategy is presented for the determination of naturally presented CTL epitopes in the context of given HLA alleles of interest from long immunogenic overlapping peptides.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20844028</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>22</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.</ArticleTitle><Pagination><MedlinePgn>11849-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01464-10</ELocationID><Abstract><AbstractText>Antigenic peptides recognized by virus-specific cytotoxic T lymphocytes (CTLs) are presented by major histocompatibility complex (MHC; or human leukocyte antigen [HLA] in humans) molecules, and the peptide selection and presentation strategy of the host has been studied to guide our understanding of cellular immunity and vaccine development. Here, a severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein-derived CTL epitope, N1 (QFKDNVILL), restricted by HLA-A*2402 was identified by a series of in vitro studies, including a computer-assisted algorithm for prediction, stabilization of the peptide by co-refolding with HLA-A*2402 heavy chain and β(2)-microglobulin (β(2)m), and T2-A24 cell binding. Consequently, the antigenicity of the peptide was confirmed by enzyme-linked immunospot (ELISPOT), proliferation assays, and HLA-peptide complex tetramer staining using peripheral blood mononuclear cells (PBMCs) from donors who had recovered from SARS donors. Furthermore, the crystal structure of HLA-A*2402 complexed with peptide N1 was determined, and the featured peptide was characterized with two unexpected intrachain hydrogen bonds which augment the central residues to bulge out of the binding groove. This may contribute to the T-cell receptor (TCR) interaction, showing a host immunodominant peptide presentation strategy. Meanwhile, a rapid and efficient strategy is presented for the determination of naturally presented CTL epitopes in the context of given HLA alleles of interest from long immunogenic overlapping peptides.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Jianxun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kawana-Tachikawa</LastName><ForeName>Ai</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vavricka</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Aikichi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Taisheng</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>George F</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>3I6L</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015234">HLA-A Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015234" MajorTopicYN="N">HLA-A Antigens</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20844028</ArticleId><ArticleId IdType="pii">JVI.01464-10</ArticleId><ArticleId IdType="doi">10.1128/JVI.01464-10</ArticleId><ArticleId IdType="pmc">PMC2977860</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Antigens. 2004 May;63(5):395-400</Citation><ArticleIdList><ArticleId IdType="pubmed">15104671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Aug;78(16):8437-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15280452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 1986 Mar;15(3):316-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2420768</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 Apr;67(4):2376-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7680391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1997 May 15;158(10):5026-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9144523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 1997 May;54(2):117-28</Citation><ArticleIdList><ArticleId IdType="pubmed">9297530</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9757107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2004 Nov;4(11):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15522678</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 Nov;42(11):5309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15528730</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2004 Dec;21(6):793-803</Citation><ArticleIdList><ArticleId IdType="pubmed">15589168</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Jan;86(Pt 1):211-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15604448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2005 Feb 4;345(5):1099-110</Citation><ArticleIdList><ArticleId IdType="pubmed">15644207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Feb 15;174(4):2212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15699154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2005 Apr;6(4):382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15735650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2005 Nov;6(11):1114-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16186824</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 2006 Jan;36(1):170-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16323248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Apr 12;24(16):3100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16494977</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16630549</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 2006;66:193-292</Citation><ArticleIdList><ArticleId IdType="pubmed">16877062</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Aug 1;351(2):466-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16690096</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2007 Jan 15;178(2):944-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17202356</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2006;1:e24</Citation><ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Aug 10;25(32):6070-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17629360</ArticleId></ArticleIdList></Reference><Reference><Citation>Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):309-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17640731</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2008 Oct 10;380(1):99-108</Citation><ArticleIdList><ArticleId IdType="pubmed">18703211</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2008 Oct;118(10):3478-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18802496</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Oct 15;181(8):5490-500</Citation><ArticleIdList><ArticleId IdType="pubmed">18832706</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 12;27(29):3912-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19490987</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2009 Sep 27;364(1530):2725-37</Citation><ArticleIdList><ArticleId IdType="pubmed">19687041</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2009 Nov;84(2):168-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19748524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2010 Apr;91(Pt 4):919-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19955560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Oct 15;202(8):1171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20831383</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2001 Aug;2(8):711-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11477407</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2001 Sep 15;98(6):1872-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11535524</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12393927</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Nov 29;298(5599):1797-800</Citation><ArticleIdList><ArticleId IdType="pubmed">12459592</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2003 Jan;18(1):53-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12530975</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Mar 22;361(9362):1017</Citation><ArticleIdList><ArticleId IdType="pubmed">12660063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Antigens. 2003 May;61(5):403-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12753660</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2003 Jul;4(7):657-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12796775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001628 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001628 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20844028
|texte= Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20844028" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |